The Canadian subsidiary of Mumbai-based pharmaceuticals firm Lupin Limited on Monday said it has launched its first brand product Zaxine in that country under a strategic licensing agreement.
The agreement with the North Carolina-based Salix Pharmaceuticals Inc grants Lupin Limited exclusive rights to promote, distribute and market the medicine in Canada.
Zaxine is a long-term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease under the cirrhosis category of disease.
As per the company, HE can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma.
"Lupin is in the process of establishing its Canadian presence and the launch opens up growth opportunities for the future," the company said in a statement.
